Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals
2014 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
$750K LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer of pharmaceutical products designed for neurodegenerative disease. The company's products use newly discovered brain pathology to design innovative therapies to slow the progression of amyotrophic lateral sclerosis and other neurone diseases to modulate stress granules, enabling physicians to prevent deoxyribonucleic acid binding protein 43 diseases in amyotrophic lateral sclerosis from the patients.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • Lab Central
  • 610 Main Street
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aquinnah Pharmaceuticals’s full profile, request a free trial.

Aquinnah Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 17-Jan-2019 $750K 0000 Completed Generating Revenue
4. Grant 21-Jun-2018 00.00 0000 Completed Generating Revenue
3. Early Stage VC 25-Apr-2017 0000 0000 Completed Generating Revenue
2. Corporate 21-Dec-2015 $5M $5M Completed Startup
1. Grant 23-Nov-2015 $680K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Aquinnah Pharmaceuticals Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cadent Therapeutics Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
0000 Venture Capital-Backed San Diego, CA 00 00.000 00000 00000
0000000 Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
000000000 00000000 Venture Capital-Backed Cambridge, MA 00 000.00 0&0
00000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

Aquinnah Pharmaceuticals Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Tau Consortium Government Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
Takeda Pharmaceutical Company Corporation Minority 000 0000 000000 0
National institutes of Neurological Disorders and Stroke Corporation Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Aquinnah Pharmaceuticals Executive Team (6)

Name Title Board
Seat
Contact
Info
Glenn Larsen Ph.D Co-Founder, Board Member, President & Chief Executive Officer
Benjamin Wolozin Ph.D Co-Founder, Board Member & Chief Scientific Officer
Manfred Weigele Ph.D Co-Founder & Scientific Advisory Board
Joshua Fox JD Board Member & Corporate Counsel
Travis Wager Vice President of Research & Board Member
You’re viewing 5 of 6 executives. Get the full list »

Aquinnah Pharmaceuticals Board Members (5)

Name Representing Role Since Contact
Info
Benjamin Wolozin Ph.D Aquinnah Pharmaceuticals Co-Founder, Board Member & Chief Scientific Officer 000 0000
Charles Kunsch Ph.D AbbVie Ventures Board Observer 000 0000
Daniel Geffken Self Board Member & Chief Financial Officer 000 0000
Joshua Fox JD Aquinnah Pharmaceuticals Board Member & Corporate Counsel 000 0000
Travis Wager Aquinnah Pharmaceuticals Vice President of Research & Board Member 000 0000